Literature DB >> 21626437

Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.

Xu Steven Xu1, Adrian Dunne, Holly Kimko, Partha Nandy, An Vermeulen.   

Abstract

The objectives of the simulation study were to evaluate the impact of BQL data on pharmacokinetic (PK) parameter estimates when the incidence of BQL data is low (e.g. ≤10%), and to compare the performance of commonly used modeling methods for handling BQL data such as data exclusion (M1) and likelihood-based method (M3). Simulations were performed by adapting the method of a recent publication by Ahn et al. (J Phamacokinet Pharmacodyn 35(4):401-421, 2008). The BQL data in the terminal elimination phase were created at frequencies of 1, 2.5, 5, 7.5, and 10% based on a one- and a two-compartment model. The impact of BQL data on model parameter estimates was evaluated based on bias and imprecision. The simulations demonstrated that for the one-compartment model, the impact of ignoring the low percentages of BQL data (≤10%) in the elimination phase was minimal. For the two-compartment model, when the BQL incidence was less than 5%, omission of the BQL data generally did not inflate the bias in the fixed-effect parameters, whereas more pronounced bias in the estimates of inter-individual variability (IIV) was observed. The BQL data in the elimination phase had the greatest impact on the volume of distribution estimate of the peripheral compartment of the two-compartment model. The M3 method generally provided better parameter estimates for both PK models than the M1 method. However, the advantages of the M3 over the M1 method varied depending on different BQL censoring levels, PK models and parameters. As the BQL percentages decreased, the relative gain of the M3 method based on more complex likelihood approaches diminished when compared to the M1 method. Therefore, it is important to balance the trade-off between model complexity and relative gain in model improvement when the incidence of BQL data is low. Understanding the model structure and the distribution of BQL data (percentage and location of BQL data) allows selection of an appropriate and effective modeling approach for handling low percentages of BQL data.

Mesh:

Year:  2011        PMID: 21626437     DOI: 10.1007/s10928-011-9201-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  6 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.

Authors:  J P Hing; S G Woolfrey; D Greenslade; P M Wright
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

Authors:  Vincent Duval; Mats O Karlsson
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

4.  Impact of censoring data below an arbitrary quantification limit on structural model misspecification.

Authors:  Wonkyung Byon; Courtney V Fletcher; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-26       Impact factor: 2.745

5.  Handling data below the limit of quantification in mixed effect models.

Authors:  Martin Bergstrand; Mats O Karlsson
Journal:  AAPS J       Date:  2009-05-19       Impact factor: 4.009

6.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

Authors:  Jae Eun Ahn; Mats O Karlsson; Adrian Dunne; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-08-07       Impact factor: 2.745

  6 in total
  11 in total

1.  Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.

Authors:  Carl Amilon; Mohammad Niazi; Anders Berggren; Magnus Åstrand; Bengt Hamrén
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

2.  Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.

Authors:  Qi Pei; Lu Huang; Jie Huang; Jing-Kai Gu; Yun Kuang; Xiao-Cong Zuo; Jun-Jie Ding; Hong-Yi Tan; Cheng-Xian Guo; Shi-Kun Liu; Guo-Ping Yang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

3.  Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.

Authors:  Mark Stroh; Matthew M Hutmacher; Jianmei Pang; Ryan Lutz; Hiroshi Magara; Julie Stone
Journal:  AAPS J       Date:  2013-01-25       Impact factor: 4.009

4.  Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.

Authors:  Kim Stuyckens; Fred Saad; Xu Steven Xu; Charles J Ryan; Matthew R Smith; Thomas W Griffin; Margaret K Yu; An Vermeulen; Partha Nandy; Italo Poggesi
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

5.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

6.  Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens.

Authors:  Gellért Balázs Karvaly; Michael N Neely; Krisztián Kovács; István Vincze; Barna Vásárhelyi; Roger W Jelliffe
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

7.  The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers.

Authors:  Sebastiaan C Goulooze; Annelieke C Kruithof; Shanavas Alikunju; Anirudh Gautam; Jacobus Burggraaf; Ingrid M C Kamerling; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.335

8.  Enrofloxacin Dose Optimization for the Treatment of Colibacillosis in Broiler Chickens Using a Drinking Behaviour Pharmacokinetic Model.

Authors:  Robin Temmerman; Ludovic Pelligand; Wim Schelstraete; Gunther Antonissen; An Garmyn; Mathias Devreese
Journal:  Antibiotics (Basel)       Date:  2021-05-19

9.  Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.

Authors:  L Ting; S Aksenov; S G Bhansali; R Ramakrishna; P Tang; D E Geller
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-12

10.  Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.

Authors:  Ana-Marija Grišić; Maria Dorn-Rasmussen; Bella Ungar; Jørn Brynskov; Johan F K F Ilvemark; Nils Bolstad; David J Warren; Mark A Ainsworth; Wilhelm Huisinga; Shomron Ben-Horin; Charlotte Kloft; Casper Steenholdt
Journal:  United European Gastroenterol J       Date:  2021-02-11       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.